**Core Concept**
ER/PR status refers to the presence or absence of estrogen receptors (ER) and progesterone receptors (PR) in breast cancer cells. This information is crucial for determining the likelihood of cancer response to hormone therapy and predicting patient outcomes.

**Why the Correct Answer is Right**
The ER/PR status is used as a prognostic variable in breast cancer because it helps predict how the tumor will respond to hormone therapy. Tumors that are ER/PR-positive are more likely to respond to hormone therapy, such as tamoxifen or aromatase inhibitors, which block the growth-promoting effects of estrogen on cancer cells. On the other hand, ER/PR-negative tumors are less likely to respond to hormone therapy and may require more aggressive treatment approaches.

**Why Each Wrong Option is Incorrect**
**Option A:** This option is incorrect because ER/PR status is not used as a prognostic variable in lung cancer, which has different predictive markers such as EGFR mutations and ALK rearrangements.

**Option B:** This option is incorrect because ER/PR status is not used as a prognostic variable in colon cancer, which has different predictive markers such as KRAS mutations and microsatellite instability.

**Option C:** This option is incorrect because ER/PR status is not used as a prognostic variable in prostate cancer, which has different predictive markers such as PSA levels and Gleason scores.

**Clinical Pearl / High-Yield Fact**
It's essential to remember that ER/PR status is not the only prognostic variable in breast cancer, and other factors such as tumor size, grade, and lymph node status should also be considered when determining treatment plans and predicting patient outcomes.

**Correct Answer:** D. Breast cancer.